Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Ondansetron for the management of chemotherapy-induced nausea and vomiting in pediatric patients: a review of the clinical effectiveness, safety and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions For the management of CINV in the pediatric population, the antiemetic effects of ondansetron plus dexamethasone appeared to be better than ondansetron alone or placebo. There was no statistically significant difference in antiemetic effect between ondansetron and tropisetron. There were some inconsistencies in the results for antiemetic effects of ondansetron compared with granisetron. Numerical values suggested that the antiemetic effects of palonosetron was greater compared to ondansetron, however it was unclear if the differences were statistically significant. It should be noted that in most instances, for each comparison there was only one relevant study. Clinical practice guidelines recommended ondansetron as a treatment option for controlling CINV in the pediatric population. Indexing Status Subject indexing assigned by CRD MeSH Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Childs; Nausea; Ondansetron; Vomiting Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32014000220 Date abstract record published 30/01/2014 |